Methods of treatment of male erectile dysfunction
AssigneeNexmed Holdings, Inc.
InventorsJames L. Yeager, Nadir Buyuktimkin, Servet Buyuktimkin
Life of this patent
Estimating the term…
Abstract
The invention provides methods for the treatment of erectile dysfunction in a patient suffering from a co-morbid condition comprising placing in the fossa navicularis of the patient an erection-inducing amount of a semi-solid vasoactive prostaglandin composition.
Claims40
A method of treating erectile dysfunction in a patient suffering from a co-morbid condition comprising the step of:
- placing an erection-inducing amount of a semi-solid composition in the fossa navicularis of the patient, the semi-solid composition comprising:
- a vasoactive prostaglandin;
- a penetration enhancer;
- a polymeric thickener selected from the group consisting of a polysaccharide gum and a polyacrylic acid polymer;
- a lipophilic component selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, and a mixture thereof;
- and
- an acidic buffer system.
A method of treating erectile dysfunction in a patient suffering from the co-morbid condition of diabetes mellitus comprising the step of placing in the fossa navicularis of the patient an erection-inducing amount of a semi-solid prostaglandin E1 composition comprising:
- a penetration enhancer;
- a shear-thinning polymeric thickener selected from the group consisting of a polysaccharide gum and a polyacrylic acid polymer;
- a component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, and a mixture thereof;
- and
- an acidic buffer system.
A method of treating erectile dysfunction in a patient suffering from the co-morbid condition of hypertension comprising the step of placing in the fossa navicularis of the patient an erection-inducing amount of a semi-solid prostaglandin E1 composition comprising:
- a penetration enhancer;
- a shear-thinning polymeric thickener selected from the group consisting of a polysaccharide gum and a polyacrylic acid polymer;
- a component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, and a mixture thereof;
- and
- an acidic buffer system.
A method of treating erectile dysfunction in a patient suffering from the co-morbid condition of cardiac disease comprising the step of placing in the fossa navicularis of the patient an erection-inducing amount of a semi-solid prostaglandin E1 composition comprising:
- a penetration enhancer;
- a shear-thinning polymeric thickener selected from the group consisting of a polysaccharide gum and a polyacrylic acid polymer;
- a component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, and a mixture thereof;
- and
- an acidic buffer system.
A method of treating erectile dysfunction in a patient having the co-morbid condition of recovering from prostatectomy comprising the step of placing in the fossa navicularis of the patient an erection-inducing amount of a semi-solid prostaglandin E1 composition comprising:
- a penetration enhancer;
- a shear-thinning polymeric thickener selected from the group consisting of a polysaccharide gum and a polyacrylic acid polymer;
- a component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, and a mixture thereof;
- and
- an acidic buffer system.
A method of treating a patient suffering from erectile dysfunction unresponsive to oral phosphodiesterase-5 inhibitor therapy comprising the step of placing in the fossa navicularis of the patient an erection-inducing amount of a semi-solid prostaglandin E1 composition comprising:
- a penetration enhancer;
- a shear-thinning polymeric thickener selected from the group consisting of a polysaccharide gum and a polyacrylic acid polymer;
- a component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, and a mixture thereof;
- and
- an acidic buffer system.
The use of prostaglandin E1;
- a penetration enhancer selected from the group consisting of an alkyl-2-(N-substituted amino)-alkanoate, an alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N-substituted amino)-alkanol alkanoate, an (N,N-disubstituted amino)-alkanol alkanoate, pharmaceutically acceptable salts thereof and mixtures thereof;
- a polymeric thickener selected from the group consisting of a polysaccharide gum and a polyacrylic acid polymer;
- a lipophilic component selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, and a mixture thereof;
- and an acidic buffer system for the preparation of a pharmaceutical composition for treating erectile dysfunction in a patient suffering from a co-morbid condition including at least one of diabetes mellitus, hypertension, cardiac disease, history of prostatectomy or erectile dysfunction unresponsive to oral phosphodiesterase-5 inhibitor therapy, whereby the pharmaceutical composition is to be placed in the fossa navicularis of the patient.
Dependencies are inferred from the claim text.